Drug Combination Details
| General Information of the Combination (ID: C84670) | |||||
|---|---|---|---|---|---|
| Name | Forskolin NP Info | + | Ponatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | CRKL | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | KCL-22 | CVCL_2091 | Chronic myelogenous leukemia | Homo sapiens | ||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| HH [Human lymphoma] | CVCL_1280 | Cutaneous T-cell non-Hodgkin lymphoma | Homo sapiens | |||
| HEK293 | CVCL_0045 | Healthy | Homo sapiens | |||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Human peripheral blood mononuclear cells | Healthy | Homo sapiens | ||||
| Experimental
Result(s) |
A synergistic combination of ponatinib- and forskolin-reduced cell viability was identified in this clinically relevant imatinib-resistant CML cell line, which also proved efficacious in other CML cell lines. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Sep;37(9):12643-12654. | |||
